Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 9/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.77 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | DAO | P14920 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.64 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.63 |
| ▸ | IDO1 | P14902 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060426 | 1.00 | FLT3 (1.00) | FLT3PDGFRBPDGFRAKDM4EMAPT | |
| Methane SCHEMBL22343918 | 0.98 | FLT3 (0.96) | FLT3PDGFRBPDGFRAKDM4EMAPT | |
| SCHEMBL2729915 | 0.88 | FLT3 (0.79) | FLT3PDGFRBPDGFRAKDM4EMAPT | |
| SCHEMBL30772489 | 0.88 | FLT3 (1.00) | FLT3PDGFRBPDGFRAABL1KIT | |
| SCHEMBL4456469 | 0.88 | FLT3 (1.00) | FLT3PDGFRBPDGFRAABL1KIT | |
| SCHEMBL31277139 | 0.87 | FLT3 (0.77) | FLT3PDGFRBPDGFRAKDM4EMAPT | |
| SCHEMBL6997369 | 0.86 | FLT3 (0.74) | FLT3PDGFRBPDGFRAKDM4EMAPT | |
| SCHEMBL31060211 | 0.86 | FLT3 (1.00) | FLT3PDGFRBPDGFRAKDM4EMAPT | |
| Indole-2-Carboxylic Acid SCHEMBL1935 | 0.85 | KDM4E (1.00) | FLT3PDGFRBPDGFRAKDM4EMAPT | |
| Indole-2-Carboxylic Acid SCHEMBL29395165 | 0.85 | KDM4E (1.00) | FLT3PDGFRBPDGFRAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000451-B2 | MAP4K4 (HGK) inhibitors | SRI INTERNATIONAL (US) | 2018-06-19 | — | — | US | claimed |
| US-20170320824-A1 | MAP4K4 (HGK) Inhibitors | SRI INTERNATIONAL (US) | 2017-11-09 | — | — | US | claimed |
| EP-3233797-A1 | MAP4K4 (HGK) Inhibitors | SRI International Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| WO-2016114816-A1 | MAP4K4 (HGK) Inhibitors | SRI INTERNATIONAL (US) | 2016-07-21 | — | — | WO | claimed |
| EP-1631291-A2 | USE OF TYROSINE KINASE INHIBITORS TO TREAT DIABETES | Hägerkvist, Robert P. (SE) | 2006-03-08 | — | — | EP | claimed |
| WO-2004105763-A2 | USE OF TYROSINE KINASE INHIBITOR TO TREAT DIABETES | HAEGERKVIST ROBERT PER (SE) | 2004-12-09 | — | — | WO | claimed |
| US-6812243-B2 | AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES | ZENTARIS AG (DE) | 2004-11-02 | — | — | US | claimed |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | ZENTARIS AG (DE) | 2003-01-09 | — | — | US | claimed |
| EP-1109785-B1 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ZENTARIS AG (DE) | 2003-01-02 | — | — | EP | claimed |
| US-6407102-B1 | TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS | ZENTARIS AG (DE) | 2002-06-18 | — | — | US | claimed |
| EP-1109785-A2 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ASTA Medica Aktiengesellschaft (DE) | 2001-06-27 | — | — | EP | claimed |
| WO-1999057117-A2 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-11-11 | — | — | WO | claimed |
| US-5741801-A | 5-HT4 receptor antagonist | SMITHKLINE BEECHAM PLC (GB) | 1998-04-21 | — | — | US | claimed |
| CN-119192175-A | Compound, pharmaceutical composition and application thereof | 北京康辰药业股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4389223-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2024-06-26 | — | — | EP | disclosed |
| CN-114805325-B | Multi-indolone Zig-Zag bipolar small molecule and preparation method and application thereof | 湖南工程学院 | 2024-02-06 | — | — | CN | disclosed |
| EP-1109785-A2 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ASTA Medica Aktiengesellschaft (DE) | 2001-06-27 | — | — | EP | disclosed |
| WO-1999057117-A2 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-11-11 | — | — | WO | disclosed |
| US-5776780-A | AUTOMATIC ANALYZING; COLORIMETRIC PHOTOMETRY | CHIMERA RESEARCH & CHEMICAL, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5516700-A | Automated urinalysis method | CHIMERA RESEARCH AND CHEMICAL, INC. (US) | 1996-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320824-A1 | MAP4K4 (HGK) Inhibitors | MAP4K4, MAP4K2, MAP4K3 | FLT3 560/4885PDGFRB 1752/4885PDGFRA 1866/4885 |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | MKI67, IDO1, CCNI | FLT3 230/4885PDGFRB 474/4885PDGFRA 542/4885 |
| US-10000451-B2 | MAP4K4 (HGK) inhibitors | MAP4K4, MAP4K2, MAP4K3 | FLT3 560/4885PDGFRB 1752/4885PDGFRA 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.